PharmaResearch Co (214450.KQ) Stock Price
PharmaResearch Co Price
Over the last 12 years PharmaResearch Co grew revenue by 32.8% annually, reaching 536.29 B KRW. Earnings per share have grown at 28.2% per year over the last 12 years. For PharmaResearch Co, the net margin of 30.8% is broadly stable versus 30.3% a few years ago. At today's price the dividend yield works out to roughly 1.70%. The payout ratio is around 23% of earnings. The dividend has grown at 33.9% per year over the past 10 years. The consensus 12-month price target for PharmaResearch Co is 612,000.00 KRW, about 180.7% above where the stock trades today. Of 17 analysts, 16 rate the stock a buy — an overall Buy consensus.
PharmaResearch Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
PharmaResearch Co business model & stock analysis
Frequently asked questions about PharmaResearch Co
Analysts currently set an average price target of 630,823.64 KRW for the PharmaResearch Co stock (median: 612,000.00 KRW), implying +189.4 % versus the latest price. The consensus is based on 17 analyst ratings.
18 analysts currently rate the PharmaResearch Co stock: 16 recommend buying, 2 holding and 0 selling. For 2026, analysts expect PharmaResearch Co to generate revenue of 692.88 B KRW and earnings per share of 19,465.57 KRW.
Converted at the current exchange rate, the PharmaResearch Co share trades at 144.67 EUR (218,000.00 KRW).
The PharmaResearch Co share (214450.KQ) is listed on 1 stock exchanges, including: KOSDAQ (Seoul) (214450.KQ).
The expected revenue of PharmaResearch Co is 692.88 B KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of PharmaResearch Co is 202.24 B KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of PharmaResearch Co is currently 11.20. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PharmaResearch Co stock.
The price-to-sales ratio (P/S) of PharmaResearch Co is currently 3.27. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PharmaResearch Co stock.
The Eulerpool Quality Score for PharmaResearch Co is 9/10.
The ISIN of PharmaResearch Co is KR7214450009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of PharmaResearch Co is 214450.KQ. The ticker symbol is used to trade PharmaResearch Co shares on the stock exchange.
PharmaResearch Co stock
PharmaResearch Co Peer Group
PharmaResearch Co Ticker
PharmaResearch Co FIGI
All fundamentals and in-depth analysis of PharmaResearch Co
Our stock analysis for PharmaResearch Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmaResearch Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.